

Technology Guidance

Nivolumab in combination with ipilimumab for treating unresectable or advanced hepatocellular carcinoma

Technology Guidance from the MOH Drug Advisory Committee

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has not recommended nivolumab in combination with ipilimumab for inclusion on the MOH List of Subsidised Drugs for treating unresectable or advanced hepatocellular carcinoma in patients who have not received prior systemic therapy. The decision was based on nivolumab in combination with ipilimumab being unlikely to represent an acceptable use of healthcare resources at the prices proposed by the company.

Clinical indication, subsidy class and MediShield Life claims eligibility for nivolumab and ipilimumab are provided in the Annex.

ANNEX

Recommendations by the MOH Drug Advisory Committee

Drug preparation	Approved clinical indication	Subsidy class	Eligible for MediShield Life claims (implementation date)
Nivolumab concentrate for solution for infusion (40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL) Ipilimumab injection concentrate (50 mg/10 mL)	Nivolumab in combination with ipilimumab for treating unresectable or advanced hepatocellular carcinoma in patients who have not received prior systemic therapy, and who have adequate liver function as assessed by the Child-Pugh scoring system. The doses of nivolumab and ipilimumab should not exceed: 1mg/kg nivolumab and 3mg/kg ipilimumab every 3 weeks for 4 doses, followed by nivolumab 240mg every 2 weeks or 480mg every 4 weeks as a single agent. Treatment should be stopped at 2 years, or earlier if disease progresses.	Not recommended for subsidy	Yes ¹ (1 Dec 2026)

¹ Please refer to [MOH's website](#) for the MediShield Life claim limit starting from the implementation date.

 Agency for Care Effectiveness - ACE  Agency for Care Effectiveness (ACE)

About the Agency

The Agency for Care Effectiveness (ACE) was established by the Ministry of Health (Singapore) to drive better decision-making in healthcare through health technology assessment (HTA), clinical guidelines, and education.

As the national HTA agency, ACE conducts evaluations to inform government funding decisions for treatments, diagnostic tests and vaccines, and produces guidance for public hospitals and institutions in Singapore.

The guidance is not, and should not be regarded as, a substitute for professional or medical advice. Please seek the advice of a qualified healthcare professional about any medical condition. The responsibility for making decisions appropriate to the circumstances of the individual patient remains with the healthcare professional.

Find out more about ACE at <https://www.ace-hta.gov.sg/about-us/>

© Agency for Care Effectiveness, Ministry of Health, Republic of Singapore

All rights reserved. Reproduction of this publication in whole or in part in any material form is prohibited without the prior written permission of the copyright holder. Requests to reproduce any part of this publication should be addressed to:

Agency for Care Effectiveness, Ministry of Health, Singapore
Email: ACE@moh.gov.sg

In citation, please credit "Agency for Care Effectiveness, Ministry of Health, Singapore" when you extract and use the information or data from the publication.